Accesswire
01 Jun 2026, 09:20 UTC · 1h ago
Source · https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvent-to-host-a-kol-event-in-stockholm-on-june-11-2026-to-discuss-updated-bi-1206-1172122
Read source
Search tags
Story key points
3 claims · impact-rated
BioInvent is reporting updated data for BI-1206 showing encouraging activity in a triple combination with rituximab and Calquence for relapsed/refractory non-Hodgkin's lymphoma. — Positive clinical data in a high-unmet-need area like rituximab-resistant NHL is a primary driver of biotech valuation.
+0.60Phase 2a study data for BI-1808 in advanced cutaneous T-cell lymphoma demonstrates meaningful and sustained responses as both a monotherapy and in combination with KEYTRUDA. — Sustained responses in a Phase 2a study provide a critical proof-of-concept for the drug's viability as a potential commercial product.
+0.50BioInvent will host a Key Opinion Leader (KOL) event on June 11, 2026, to discuss the clinical progress and commercial potential of BI-1206 and BI-1808. — KOL events are designed to build market confidence and analyst interest, though they are catalyst events rather than data releases themselves.
+0.20Ticker attribution
Continue reading
6 related stories
Model heads
The company is hosting a KOL event to showcase encouraging clinical progress and commercial potential for its lead programs BI-1206 and BI-1808.
Mentioned as a partner whose therapy KEYTRUDA showed meaningful and sustained responses in combination with BioInvent's BI-1808.
Mentioned only as a provider of clinical supply for a study, with no impact on its business outlook.
Impact vectors
2 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
MarketBeat
9h ago
